BACKGROUND: Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by heterozygous mutations in mismatch repair (MMR) genes. Approximately 85 % of genetically defined HNPCC patients have germline mutations in MLH1 and MSH2. HNPCC patients are at increased risk of developing extracolonic cancers. The early age of onset, predominantly right-sided colon cancers, and synchronous and metachronous cancers are other features of the syndrome. HNPCC shows heterogeneous clinical phenotypes, and differences in gene mutation frequencies have been observed in some countries. Several investigators have tried to correlate the phenotype with the affected gene. METHODS: A total of 46 individuals from 22 unrelated families, of the 264 families fulfilling the inclusion criteria, with deleterious mutations in MLH1, MSH2, or MSH6 genes were identified. We evaluated these clinicopathological features in their relation to different genetic parameters (gene mutated, type of mutation, or alteration of the MMR system in high-risk families) in order to establish a relationship between the phenotype and the genotype in our series. RESULTS: The phenotype of the disease seems not to be influenced by the type of mutation, but rather by the mutated gene. The presence of multiple tumors is associated with mutations in the MSH2 gene. The mean age at diagnosis of the first colorectal cancer (CRC) was almost identical in families with mutations in MLH1 and MSH2, about 50 years of age, but this age may increase by almost 10 years for MSH6 mutation carriers. CONCLUSION: The identification of genotype-phenotype correlations could provide a more specific surveillance program focused on the individualized risk.
BACKGROUND:Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by heterozygous mutations in mismatch repair (MMR) genes. Approximately 85 % of genetically defined HNPCC patients have germline mutations in MLH1 and MSH2. HNPCC patients are at increased risk of developing extracolonic cancers. The early age of onset, predominantly right-sided colon cancers, and synchronous and metachronous cancers are other features of the syndrome. HNPCC shows heterogeneous clinical phenotypes, and differences in gene mutation frequencies have been observed in some countries. Several investigators have tried to correlate the phenotype with the affected gene. METHODS: A total of 46 individuals from 22 unrelated families, of the 264 families fulfilling the inclusion criteria, with deleterious mutations in MLH1, MSH2, or MSH6 genes were identified. We evaluated these clinicopathological features in their relation to different genetic parameters (gene mutated, type of mutation, or alteration of the MMR system in high-risk families) in order to establish a relationship between the phenotype and the genotype in our series. RESULTS: The phenotype of the disease seems not to be influenced by the type of mutation, but rather by the mutated gene. The presence of multiple tumors is associated with mutations in the MSH2 gene. The mean age at diagnosis of the first colorectal cancer (CRC) was almost identical in families with mutations in MLH1 and MSH2, about 50 years of age, but this age may increase by almost 10 years for MSH6 mutation carriers. CONCLUSION: The identification of genotype-phenotype correlations could provide a more specific surveillance program focused on the individualized risk.
Authors: Laura Valle; Jose Perea; Pablo Carbonell; Victoria Fernandez; Ana M Dotor; Javier Benitez; Miguel Urioste Journal: J Clin Oncol Date: 2007-01-16 Impact factor: 44.544
Authors: H T Lynch; T C Smyrk; P Watson; S J Lanspa; J F Lynch; P M Lynch; R J Cavalieri; C R Boland Journal: Gastroenterology Date: 1993-05 Impact factor: 22.682
Authors: Fay Kastrinos; Bhramar Mukherjee; Nabihah Tayob; Fei Wang; Jennifer Sparr; Victoria M Raymond; Prathap Bandipalliam; Elena M Stoffel; Stephen B Gruber; Sapna Syngal Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen Journal: Gastroenterology Date: 2004-07 Impact factor: 22.682
Authors: Johanne Geary; Peter Sasieni; Richard Houlston; Louise Izatt; Ros Eeles; Stewart J Payne; Samantha Fisher; Shirley V Hodgson Journal: Fam Cancer Date: 2007-10-16 Impact factor: 2.375
Authors: H F Vasen; J T Wijnen; F H Menko; J H Kleibeuker; B G Taal; G Griffioen; F M Nagengast; E H Meijers-Heijboer; L Bertario; L Varesco; M L Bisgaard; J Mohr; R Fodde; P M Khan Journal: Gastroenterology Date: 1996-04 Impact factor: 22.682
Authors: Manon Suerink; Heleen M van der Klift; Sanne W Ten Broeke; Olaf M Dekkers; Inge Bernstein; Gabriel Capellá Munar; Encarna Gomez Garcia; Nicoline Hoogerbrugge; Tom G W Letteboer; Fred H Menko; Annika Lindblom; Arjen Mensenkamp; Pal Moller; Theo A van Os; Nils Rahner; Bert J W Redeker; M J W Olderode-Berends; Maran Olderode; Liesbeth Spruijt; Yvonne J Vos; Anja Wagner; Hans Morreau; Frederik J Hes; Hans F A Vasen; Carli M Tops; Juul T Wijnen; Maartje Nielsen Journal: Genet Med Date: 2015-06-25 Impact factor: 8.822
Authors: C Guillén-Ponce; R Serrano; A B Sánchez-Heras; A Teulé; I Chirivella; T Martín; E Martínez; R Morales; L Robles Journal: Clin Transl Oncol Date: 2015-11-19 Impact factor: 3.405
Authors: Margarita Raygada; Mark Raffeld; Andrew Bernstein; Markku Miettinen; John Glod; Marybeth S Hughes; Karlyne Reilly; Brigitte Widemann; Jaydira Del Rivero Journal: Am J Med Genet A Date: 2021-02-21 Impact factor: 2.802